IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ANDREOLI, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.560
EU - Europa 8.167
AS - Asia 7.840
SA - Sud America 1.811
Continente sconosciuto - Info sul continente non disponibili 476
AF - Africa 246
OC - Oceania 24
AN - Antartide 1
Totale 35.125
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.075
SG - Singapore 2.671
CN - Cina 2.270
DE - Germania 2.263
BR - Brasile 1.485
UA - Ucraina 1.203
IT - Italia 1.186
HK - Hong Kong 1.013
PL - Polonia 782
RU - Federazione Russa 636
VN - Vietnam 624
FR - Francia 463
FI - Finlandia 457
GB - Regno Unito 446
TR - Turchia 308
BD - Bangladesh 288
IE - Irlanda 242
CA - Canada 225
IN - India 180
AR - Argentina 114
MX - Messico 91
SE - Svezia 91
NL - Olanda 78
ZA - Sudafrica 74
IQ - Iraq 65
EC - Ecuador 58
JP - Giappone 53
ID - Indonesia 50
ES - Italia 48
CO - Colombia 46
PK - Pakistan 40
NG - Nigeria 39
AT - Austria 38
SA - Arabia Saudita 36
VE - Venezuela 35
CZ - Repubblica Ceca 31
JM - Giamaica 30
CR - Costa Rica 27
UZ - Uzbekistan 27
MA - Marocco 26
PH - Filippine 24
AU - Australia 23
EG - Egitto 23
BE - Belgio 21
CL - Cile 21
JO - Giordania 21
PY - Paraguay 21
LT - Lituania 19
AE - Emirati Arabi Uniti 18
DZ - Algeria 17
TT - Trinidad e Tobago 17
CH - Svizzera 16
GR - Grecia 16
TH - Thailandia 16
EU - Europa 15
HN - Honduras 15
IL - Israele 15
KE - Kenya 15
PE - Perù 15
SV - El Salvador 15
HR - Croazia 14
AL - Albania 13
KZ - Kazakistan 13
NI - Nicaragua 13
PT - Portogallo 12
DK - Danimarca 10
MK - Macedonia 10
MY - Malesia 10
NP - Nepal 10
PR - Porto Rico 10
ET - Etiopia 9
GT - Guatemala 9
RS - Serbia 9
TN - Tunisia 9
UY - Uruguay 9
BB - Barbados 8
RO - Romania 8
SK - Slovacchia (Repubblica Slovacca) 8
BG - Bulgaria 7
BH - Bahrain 7
EE - Estonia 7
GE - Georgia 7
HU - Ungheria 7
KR - Corea 7
LY - Libia 7
AZ - Azerbaigian 6
DO - Repubblica Dominicana 6
LB - Libano 6
PS - Palestinian Territory 6
BO - Bolivia 5
GP - Guadalupe 5
IR - Iran 5
KG - Kirghizistan 5
KW - Kuwait 5
LU - Lussemburgo 5
NO - Norvegia 5
SC - Seychelles 5
SN - Senegal 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
Totale 34.589
Salva come PNG Salva come JPEG
Città #
Ashburn 1.523
Fairfield 1.489
Singapore 1.379
Woodbridge 1.175
Hong Kong 1.003
San Jose 927
Houston 848
Jacksonville 835
Warsaw 771
Seattle 576
The Dalles 574
Cambridge 545
Wilmington 514
Council Bluffs 494
Ann Arbor 491
Beijing 487
New York 442
Princeton 439
Chandler 346
Helsinki 291
Los Angeles 288
Istanbul 247
Dublin 239
Lauterbourg 234
Nanjing 227
Ho Chi Minh City 200
Dallas 190
Columbus 169
São Paulo 156
Munich 149
Brescia 139
Hanoi 136
Milan 135
Santa Clara 127
Moscow 117
Buffalo 110
Chicago 107
Redondo Beach 107
San Diego 103
Nanchang 102
Nürnberg 102
San Francisco 98
Des Moines 96
Changsha 86
Shanghai 86
London 72
North Bergen 70
Shenyang 69
Hebei 65
Atlanta 64
Lancaster 64
Orem 63
Nuremberg 57
Rome 55
Toronto 55
Phoenix 54
Rio de Janeiro 52
Turku 52
Tokyo 47
Chennai 44
Jinan 43
Montreal 43
Denver 41
Brooklyn 40
Johannesburg 39
Abuja 37
Hangzhou 35
Tianjin 35
Belo Horizonte 34
Bergamo 32
Dearborn 32
Jiaxing 32
Mexico City 32
Porto Alegre 32
Brasília 30
Verona 30
Frankfurt am Main 29
Guangzhou 28
Haiphong 28
Poplar 28
Zhengzhou 28
Amsterdam 27
Curitiba 27
Da Nang 27
Dhaka 26
Manchester 26
Tashkent 25
Boardman 24
Charlotte 24
Dong Ket 24
Biên Hòa 23
Boston 23
Romola 23
Bologna 22
San José 22
Kunming 21
Guayaquil 20
Stockholm 20
Turin 20
Amman 19
Totale 20.933
Salva come PNG Salva come JPEG
Nome #
9A.07: CARDIOVASCULAR TARGET ORGAN DAMAGE IN PREMENOPAUSAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IN CONTROLS. ARE THERE ANY DIFFERENCES? 362
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome 341
Role of guanylate binding protein-1 in vascular defects associated with chronic inflammatory diseases. 304
The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation 265
2023 ACR/EULAR antiphospholipid syndrome classification criteria 253
Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis 251
Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? 250
Long-term outcome of children of rheumatic disease patients 243
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 227
The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus 223
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 222
Antirheumatic drugs and reproduction in women and men with chronic arthritis. 218
SINDROME DA ANTICORPI ANTIFOSFOLIPIDI E LESIONI PUNTIFORMI DELLA SOSTANZA BIANCA ALLA RISONANZA MAGNETICA. QUAL E' IL LORO SIGNIFICATO? VALUTAZIONE DI 169 PAZIENTI CON MANIFESTAZIONI NEUROLOGICHE 214
14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome 213
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends 211
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 201
A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus 199
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. 196
A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution 194
Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. 193
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 193
Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits. 192
Typing TREX1 Gene In Patients With Systemic Lupus Erythematosus. 192
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 192
Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes 191
Anti-phospholipid antibodies 190
Management of thrombotic and obstetric antiphospholipid syndrome: A systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults 188
Children born to SLE and APS mothers 186
A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus 183
Subpopulations of anti-β₂glycoprotein I antibodies with different pathogenic potential: fine specificity against the domains of β₂glycoprotein I 182
Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. 182
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome 182
Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis 181
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 181
Antiphospholipid antibodies mediate autoimmunity against dying cells. 178
Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 178
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 177
25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies. 176
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 176
Inflammatory molecules: A target for treatment of systemic autoimmune diseases. 174
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 172
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 171
Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. 169
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 169
Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome 168
The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes 168
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome 167
Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. 166
Long-term outcome of children born from mothers with autoimmune diseases 166
Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study 165
Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D 164
Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? 160
Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. 160
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 160
APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. 159
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 159
Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome 159
Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: Results from a multicenter study of 283 pregnancies 159
State of the art: Reproduction and pregnancy in rheumatic diseases. 158
Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7 158
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. 158
Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period-a cross-sequential study based on COVAD surveys 157
Beyond the "syndrome": antiphospholipid antibodies as risk factors. 157
Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome. 157
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre et al 157
Antiphospholipid antibody profile: implications for the evaluation and management of patients. 156
ANTI-BETA2 GLYCOPROTEIN I-DOMAIN 1 AUTOANTIBODIES: COMPARISON BETWEEN TWO METHODS OF DETECTION 156
Management of recurrent thrombosis in antiphospholipid syndrome 156
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 155
Small extracellular vesicle-delivered microRNAs promote IFN-alpha secretion by plasmacytoid DCs via TLR7 155
An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases 155
Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? 154
European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO) 154
PROSPECTIVELY FOLLOWED PREGNANCIES IN PATIENTS WITH SYSTEMIC VASCULITIS: STILL MANY PROBLEMS ON BOTH FOETAL AND MATERNAL SIDE 152
Are the current attempts at standardization of antiphospholipid antibodies still useful? Emerging technologies signal a shift in direction. 151
Pregnancy in patients with autoimmune disease: A reality in 2016 151
Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. 150
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. 150
EFFICACY AND SAFETY OF CYCLOSPORINE-A DURING PREGNANCY IN AUTOIMMUNE DISEASES 150
Predictors of maternal and fetal complications in SLE patients: a prospective study 150
Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues. 148
Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases 148
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 148
I polimorfismi della metilentetraidrofolatoreduttasi (MTHFR) nel trattamento con methotrexate di pazienti con artrite reumatoide. Revisione della letteratura ed esperienza personale. 147
WINTER LUPUS FLARES ARE ASSOCIATED WITH LOWER VITAMIN D LEVELS IN A RETROSPECTIVE LONGITUDINAL STUDY OF ITALIAN PATIENTS 147
Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–Goutières Syndrome 146
Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. 146
Infertility in women with systemic autoimmune diseases 145
Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: may antinucleosome antibodies be predictive? 143
IL COMPLEMENTO NELLA GRAVIDANZA DI DONNE AFFETTE DA SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA 141
A PROSPECTIVE STUDY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS SUPPLEMENTED WITH TWO DIFFERENT REGIMES OF VITAMIN D: EFFICACY AND SAFETY AT SIX MONTHS OF FOLLOW-UP 141
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy 140
Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group 140
THE FINE SPECIFICITY OF ANTI-BETA2GLYCOPROTEIN I ANTIBODIES IN SYSTEMIC AUTOIMMUNE DISEASES IS PREFERENTIALLY DIRECTED AGAINST DOMAIN 1 139
Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. 139
DOMAIN 1 IS THE MAIN SPECIFICITY OF ANTI-BETA2GPI ANTIBODIES IN SYSTEMIC AUTOIMMUNE DISEASES 139
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 139
Neonatal effects of maternal antiphospholipid syndrome. 138
THE EFFECTS ON T-CELL IMMUNE PHENOTYPE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH TWO DIFFERENT REGIMENS OF VITAMIN D SUPPLEMENTATION 138
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 138
Totale 17.662
Salva come PNG Salva come JPEG
Categoria #
all - tutte 169.830
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 169.830
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.315 0 0 0 102 20 102 57 132 103 206 172 421
2022/20231.285 248 16 32 58 125 377 5 107 176 4 65 72
2023/20241.814 108 64 144 158 66 345 56 78 456 33 26 280
2024/20254.520 84 71 66 530 408 411 509 247 392 351 915 536
2025/20269.760 856 1.383 744 1.497 911 608 1.351 371 549 869 364 257
2026/20273.340 467 504 931 1.438 0 0 0 0 0 0 0 0
Totale 35.125